Table 1.
Comparison of perioperative findings between post-transplant dyslipidemia and non-post-transplant dyslipidemia groups
| PTDL (n = 278) | Non-PTDL (n = 118) | P value | |
| Recipient factors | |||
| Age (yr) | 48.2 ± 9.6 | 49.1 ± 9.1 | 0.411 |
| Male, n (%) | 237 (85.3) | 102 (86.4) | 0.758 |
| BMI (kg/m2) | 23.2 ± 3.2 | 22.3 ± 2.9 | 0.012 |
| MELD score | 20.9 ± 10.9 | 20.6 ± 11.7 | 0.777 |
| Laboratory value | |||
| Creatinine (μmol/L) | 65.0 (53.0-83.8) | 66.0 (55.0-78.0) | 0.925 |
| Albumin (g/L) | 34.7 (31.0-38.2) | 35.5 (32.2-39.6) | 0.218 |
| TB (μmol/L) | 63.5 (28.0-335.5) | 58.5 (22.3-205.8) | 0.066 |
| INR | 1.5 (1.3-1.9) | 1.4 (1.2-1.7) | 0.087 |
| AST (U/L) | 66.0 (37.0-128.8) | 71.5 (38.3-125.5) | 0.694 |
| ALT (U/L) | 43 (24.0-93.3) | 40.5 (26.0-125.0) | 0.621 |
| TC (mg/dL) | 100.5 (65.7-139.2) | 104.4 (73.5-135.3) | 0.947 |
| TG (mg/dL) | 88.6 (62.0-115.1) | 70.9 (53.1-97.4) | 0.017 |
| HDLC (mg/dL) | 23.2 (11.6-34.8) | 27.1 (15.5-42.5) | 0.024 |
| LDLC (mg/dL) | 47.6 (27.1-73.5) | 46.4 (30.9-69.6) | 0.676 |
| VLDLC (mg/dL) | 23.2 (15.5-38.7) | 19.3 (11.6-30.9) | 0.052 |
| FBG (mmol/L) | 6.3 (5.3-8.0) | 6.0 (5.3-7.4) | 0.328 |
| Cirrhosis, n (%) | 206 (74.1) | 94 (79.7) | 0.238 |
| HCC, n (%) | 108 (38.8) | 61 (51.7) | 0.018 |
| HBV status, n (%) | |||
| HBsAg positive | 215 (77.3) | 102 (86.4) | 0.038 |
| HBeAg positive | 81 (29.1) | 27 (22.9) | 0.201 |
| HBV DNA > 1000 copies/mL | 39 (14.0) | 18 (15.3) | 0.751 |
| Pre-LT AVT | 108 (38.8) | 52 (44.1) | 0.333 |
| Comorbidities, n (%) | |||
| Hepatic encephalopathy | 50 (18.0) | 25 (21.2) | 0.457 |
| Hepatorenal syndrome | 22 (7.9) | 10 (8.5) | 0.851 |
| Gastrointestinal bleeding | 57 (20.5) | 14 (11.9) | 0.040 |
| Ascites | 104 (37.4) | 31 (26.3) | 0.032 |
| Donor factors | |||
| Age (yr) | 38.8 ± 12.3 | 41.3 ± 12.8 | 0.071 |
| Male, n (%) | 235 (84.5) | 99 (83.9) | 0.874 |
| Cause of death, n (%) | |||
| Trauma | 171 (61.5) | 71 (60.2) | 0.802 |
| CVA | 87 (31.3) | 37 (31.4) | 0.934 |
| Other | 21 (7.6) | 10 (8.5) | 0.755 |
| DBD (vs DCD) | 49 (17.6) | 17 (14.4) | 0.432 |
| BMI (kg/m2) | 22.6 ± 2.6 | 23.0 ± 2.7 | 0.169 |
| Graft weight (kg) | 1.4 ± 0.3 | 1.4 ± 0.3 | 0.228 |
| Macrovesicular steatosis, n (%) | 50 (18.0) | 22 (18.6) | 0.877 |
| Creatinine (μmol/L) | 77.0 (56.5-118.5) | 82.2 (56.1-121.3) | 0.685 |
| Albumin (g/L) | 31.0 (28.0-36.5) | 30.9 (26.7-36.7) | 0.474 |
| TB (μmol/L) | 14.1 (9.1-23.4) | 16.5 (11.1-26.5) | 0.078 |
| AST (U/L) | 52.0 (33.0-87.2) | 51.5 (31.3-94.5) | 0.694 |
| ALT (U/L) | 34.0 (22.0-69.0) | 39.0 (22.5-76.3) | 0.345 |
| Operative factors | |||
| WIT (min) | 50.7 ± 14.3 | 47.0 ± 10.8 | 0.006 |
| CIT (h) | 8.4 ± 3.1 | 8.7 ± 3.4 | 0.359 |
| Blood loss (L) | 1.0 (0.8-2.0) | 1.0 (0.8-1.5) | 0.117 |
| Immunosuppressant, n (%) | |||
| IL2R antibody | 204 (73.4) | 93 (78.8) | 0.254 |
| Corticosteroid | 156 (56.1) | 58 (49.2) | 0.204 |
| Tacrolimus | 245 (88.1) | 103 (87.3) | 0.814 |
PTDL: Post-transplant dyslipidemia; BMI: Body mass index; MELD: Model for end-stage liver disease; TB: Total bilirubin; INR: International normalized ratio; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TC: Total cholesterol; TG: Triglyceride; HDLC: High-density lipoprotein cholesterol; LDLC: Low density lipoprotein cholesterol; VLDLC: Very low-density lipoprotein cholesterol; FBG: Fasting blood glucose; HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; LT: Liver transplantation; AVT: Antiviral treatment; CVA: Cerebral vascular accident; DBD: Donation after brain death; DCD: Donor after circulatory death; WIT: Warm ischemia time; CIT: Cold ischemia time.